A Phase 1 Multicenter, Dose Escalation Study of CBT-501 in Subjects With Select Advanced or Relapsed/Recurrent Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Genolimzumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Liver cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors CBT Pharmaceuticals
- 09 Sep 2018 Planned number of patients changed from 50 to 114.
- 09 Sep 2018 Planned End Date changed from 1 Mar 2019 to 1 Dec 2021.
- 09 Sep 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2020.